文献速递白血病

儿童急性淋巴细胞白血病中ROR1阳性细胞的表达及双特异性T细胞衔接器治疗

Expression and treatment of ROR1+ cells with bispecific T-cell engagers in pediatric acute lymphoblastic leukemia.
PubMed 文献 · Blood Adv · 2025-01-01

研究检测了儿童B细胞前体急性淋巴细胞白血病(BCP-ALL)和T细胞急性淋巴细胞白血病(T-ALL)中ROR1的表达,发现T-ALL的ROR1阳性细胞比例显著高于BCP-ALL,且ROR1阳性白血病增殖细胞在诱导治疗后存活并增多。体外和体内实验显示ROR1双特异性T细胞衔接器可降低白血病细胞存活和疾病负荷,作者认为ROR1是重要治疗靶点,ROR1双特异性T细胞衔接器可考虑用于难治性BCP-ALL。

要点

  • T-ALL的ROR1阳性细胞比例中位数13.8%显著高于BCP-ALL的6%(P = .02)。
  • ROR1阳性白血病增殖细胞在BCP-ALL和T-ALL中均存活诱导治疗且治疗后数量增加。
  • 体外ROR1双特异性T细胞衔接器使BCP-ALL存活降至44%、T-ALL降至58%,对照T细胞组为94%和84%(P ≤ .01)。

核心结论

  • ROR1阳性细胞对当前治疗耐药,使其成为重要靶点;ROR1双特异性T细胞衔接器体内效果至少与CD19双特异性T细胞衔接器相当,可考虑用于难治性BCP-ALL的治疗。

研究设计与样本

  • 研究检测儿童BCP-ALL和T-ALL病例中ROR1的表达,并在原代病例中体外和体内测试ROR1双特异性T细胞衔接器。

主要发现

  • ROR1阳性细胞比例在T-ALL中位数13.8%(范围2.9%-87%)显著高于BCP-ALL的6%(范围0.3%-83%),P = .02。
  • 抗原密度在BCP-ALL中位数1027(范围876-2588)低于T-ALL的1089(范围865-1527)。
  • 白血病增殖细胞中ROR1水平在CD34-/CD19+和CD34-/CD7+亚群最高。
  • ROR1阳性白血病增殖细胞在BCP-ALL和T-ALL中均存活诱导治疗,且治疗后数量增加。
  • 体外加入ROR1双特异性T细胞衔接器使ALL存活降至BCP-ALL 44%和T-ALL 58%,对照T细胞组为94%和84%(P ≤ .01)。

临床怎么用

  • 作者认为ROR1双特异性T细胞衔接器体内效果至少与CD19双特异性T细胞衔接器相当,可考虑用于难治性BCP-ALL的治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Receptor tyrosine kinase-like orphan receptor (ROR)1 is overexpressed in some hematological cancers but has low expression in normal tissues, making it a potential therapeutic target. We investigated this therapeutic potential in childhood B-cell precursor (BCP) and T-cell acute lymphoblastic leukemia (T-ALL) cases. The proportion of ROR1+ cells was significantly higher in T-ALL (median, 13.8%; range, 2.9%-87%) than BCP-ALL (6%, 0.3%-83%, P = .02). Antigen density was also lower in BCP-ALL (median, 1027; range, 876-2588) compared to T-ALL (1089, 865-1527). In leukemia propagating cells (LPCs), ROR1 levels were highest in CD34-/CD19+ and CD34-/CD7+ subpopulations. Notably, ROR1+ LPC, in both BCP-ALL and T-ALL, survived induction therapy and their numbers increased post treatment. Subsequently, ROR1 bispecific T-cell engagers (Teng) were tested on primary cases in vitro and in vivo. Addition of ROR1 Teng in vitro reduced ALL survival to 44% in BCP-ALL and 58% in T-ALL, compared to T cells alone (94% and 84%, respectively; P ≤ .01). When NOD.Cg-PrkdcscidIl2rγtm1Wjl/SzJ mice engrafted with primary leukemia were treated with ROR1 Teng, disease burden was reduced by up to 520-fold (from 15.6% to 0.03%) in ROR1+ cells and 68-fold (58% to 0.9%) in CD19+ cells in BCP-ALL. In T-ALL cases, there was a fourfold reduction (from 1.2% to 0.3%) in ROR1+ and 2.3-fold (from 83.7% to 36.7%) in CD7+ levels. This resistance of ROR1+ cells to current therapies makes it an important target. Moreover, as ROR1 Teng were at least comparable to CD19 Teng in vivo, they could be considered for the treatment of refractory BCP-ALL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Diamanti P, Bailey BK, Iheanacho OE, et al. Expression and treatment of ROR1+ cells with bispecific T-cell engagers in pediatric acute lymphoblastic leukemia. Blood Adv. 2025. PMID: 40238899. doi:10.1182/bloodadvances.2024013814

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。